The Shifting Landscape of Female Infertility in India: A Comprehensive Review of Epidemiological Trends, Emerging Etiologies, and Clinical Interventions

Rijwan Rafiyoddin Shaikh¹*, Dr Sufiyan Ahmad², Mohsin Shamsuzzoha Shaikh¹

 

1. Department of Pharmaceutics, Royal College of Pharmaceutical Education & Research, Malegaon

2. Department of Pharmacognosy, Gangamai College of Pharmacy, Nagaon, Dhule.

 

*Correspondence: sk.riz91@gmail.com;

DOI: https://doi.org/10.71431/IJRPAS.2026.5407

Article Information		Abstract
Research Article Received: 07/04/2026 Accepted: 16/04/2026 Published:30/04/2026   Keywords Female Infertility; Polycystic Ovary Syndrome; Endometriosis; Endocrine Disruptors; Microplastics; Assisted Reproductive Technology;		India is undergoing a profound demographic transition, characterized by a rapid decline in the Total Fertility Rate (TFR) to sub-replacement levels. While indicative of population stabilization, this macro-level shift masks an escalating public health crisis: a soaring prevalence of involuntary childlessness. This review synthesizes recent epidemiological data, molecular studies, and clinical trials up to 2026 to evaluate the changing etiologies of female infertility in India, focusing on metabolic disorders, environmental toxicants, lifestyle shifts, and the integration of Assisted Reproductive Technology (ART).Primary and secondary infertility now affect approximately 8% of reproductive-aged Indian women. This surge is multifactorial. Delayed motherhood contributes significantly to age-related oocyte degradation. Endocrine and inflammatory pathologies, notably Polycystic Ovary Syndrome (PCOS)—affecting up to 17.4% of urban cohorts—and endometriosis, are rising sharply. Infectious etiologies like Genital Tuberculosis (GTB) remain a "hidden epidemic." Crucially, the modern exposome, comprising elevated ambient fine particulate matter, endocrine-disrupting chemicals (EDCs), and microplastics, profoundly impairs ovarian reserve and embryogenesis. Furthermore, diets rich in ultra-processed foods (UPFs) and chronic psychosocial stress disrupt neuroendocrine pathways, further diminishing fertility. While ART and Artificial Intelligence (AI) offer advanced clinical solutions, India's recent ART (Regulation) Act, 2021 poses new socio-legal and access challenges. Reversing the infertility trend in India requires a holistic paradigm integrating precision diagnostics, rigorous environmental regulations, nutritional reform, and inclusive legislative frameworks to protect reproductive autonomy and mitigate toxicant exposure.

 

INTRODUCTION

India is currently navigating a profound and unprecedented demographic transition, shifting from a historical paradigm characterized by high fertility rates and rapid population expansion to a complex era marked by declining birth rates and an emerging crisis of involuntary childlessness. The Total Fertility Rate (TFR) in India has experienced a precipitous decline, dropping from 3.4 children per woman during the 1992-1993 period to an average of 2.0 in the 2019-2021 period, officially falling below the population replacement threshold of 2.1.¹ While this macro-level demographic stabilization is largely celebrated as a triumph of improved female literacy, delayed marital age, expanded access to modern contraception, and the success of voluntary family planning initiatives, these aggregated national statistics obscure a parallel, insidious, and rapidly accelerating public health crisis: the soaring prevalence of female infertility.¹

The contemporary scientific and sociological discourse surrounding Indian demography must pivot from the antiquated, mid-twentieth-century anxiety of overpopulation to the immediate, lived reality of millions of individuals facing unmet reproductive goals.³ A growing cohort of Indian women who actively desire to conceive are increasingly unable to do so naturally.³ Recent comprehensive meta-analyses and rigorous epidemiological surveillance indicate that the pooled prevalence of infertility among Indian women of reproductive age (15–49 years) sits at approximately 8%, with primary infertility constituting the vast majority of these cases.⁵ This epidemiological surge is not merely a downstream byproduct of delayed maternal age, although that plays a critical role; rather, it is a highly complex, multifactorial phenomenon driven by a convergence of shifting reproductive pathologies, a rapidly degrading environmental exposome, ubiquitous dietary transformations, and pervasive, chronic psychosocial stress.⁴

As the etiology of female infertility becomes increasingly intricate, transitioning from predominantly structural and infectious causes to metabolic, environmental, and epigenetic origins, the medical and scientific response has catalyzed exponential growth in the Assisted Reproductive Technology (ART) sector.¹¹ This clinical expansion is accompanied by unprecedented technological breakthroughs, particularly in the realms of artificial intelligence, epigenetics, and non-invasive molecular diagnostics.¹¹ Simultaneously, this rapid medicalization of human reproduction has necessitated the implementation of stringent, though highly contested, socio-legal frameworks aimed at governing reproductive labor, gamete donation, and commercial surrogacy.¹⁵

This report provides an exhaustive, systemic review of the escalating rates of female infertility in India. It meticulously analyzes the intersecting epidemiological, pathological, environmental, technological, and legislative vectors defining the current crisis, offering a nuanced synthesis of the latest clinical data, molecular research, and public policy implications.

Demographic Transitions and the Epidemiology of Female Infertility

National and Regional Fertility Variations

The decline in India's Total Fertility Rate is not a uniform, monolithic trend; instead, it is characterized by stark regional heterogeneity that deeply reflects the nation's vast socioeconomic, cultural, and educational divides. According to comprehensive data derived from five successive rounds of the National Family Health Survey (NFHS-1 through NFHS-5), the national TFR has fallen by over 41.17%.¹ However, the geospatial distribution of this demographic shift highlights distinct regional realities.¹

States with historically higher indices of multidimensional poverty, predominantly agrarian economies, and lower female literacy rates—such as Bihar (3.0), Meghalaya (2.9), and Uttar Pradesh (2.4)—remain stubbornly above the replacement level, continuing to drive national population momentum.¹ Conversely, states and union territories that have experienced rapid urbanization and higher educational attainment, such as Sikkim (1.1), Goa (1.3), Chandigarh (1.4), and Jammu and Kashmir (1.4), exhibit sub-replacement fertility rates that are strikingly akin to those of rapidly aging, post-industrial nations in Western Europe and East Asia.³

Table 1: Longitudinal Evolution of Total Fertility Rates across selected Indian States and Union Territories (Data derived from NFHS longitudinal reports).¹

State / Union Territory	TFR (NFHS-1: 1992-93)	TFR (NFHS-5: 2019-21)	Percentage Decline	Current Demographic Sta tus
India (National Average)	3.4	2.0	~41.17%	Below Replacement
Bihar	4.0	3.0	25.00%	Above Replacement
Meghalaya	3.7	2.9	21.62%	Above Replacement
Uttar Pradesh	4.8	2.4	50.00%	Above Replacement
Kerala	2.0	1.8	10.00%	Below Replacement
Delhi	3.0	1.6	46.67%	Below Replacement
Jammu and Kashmir	3.1	1.4	54.84%	Severely Below Replacement
Goa	1.9	1.3	31.58%	Severely Below Replacement
Sikkim	2.8	1.1	60.71%	Severely Below Replacement

 

In the context of involuntary childlessness, an analysis of NFHS-5 data concerning primary infertility reveals alarming trends. Among Indian women who have been married for at least five years and are currently in a marital union, the national prevalence of primary infertility is 18.7 per 1,000 women.¹⁹ This prevalence rate exhibits a dramatic inverse relationship with the duration of the marriage; the prevalence peaks at an astonishing 42.9 per 1,000 for those married for only one year, gradually decreasing as couples achieve eventual conception over time.¹⁹

State-level surveillance indicates that regions such as Goa, Lakshadweep, and Chhattisgarh currently exhibit the highest proportionate burdens of primary infertility.¹⁹ Furthermore, the urban-rural epidemiological divide remains highly pronounced. The TFR in urban India stands at an alarmingly low 1.6, compared to 2.1 in rural domains.² The elevated incidence of subfertility in urban centers is strongly, though complexly, correlated with a matrix of factors: delayed marital age, intensive career aspirations leading to the postponement of childbearing, disproportionate exposure to environmental pollutants, and the rapid adoption of sedentary lifestyles.⁴ While rural populations generally marry younger and benefit from higher natural conception rates, the progressive penetration of urban lifestyle habits into rural areas is slowly eroding this historical fertility advantage.²⁰

The Narrowing Window of Fertility and the Paradigm of Delayed Motherhood

A fundamental, structural demographic shift actively fueling the modern infertility crisis is the systemic postponement of first-time motherhood. When examining the data superficially, the median age at which an Indian woman has her first child has only marginally increased over the past two decades, currently sitting at just over 21 years nationally.²³ However, decomposing this aggregate statistic reveals a monumental shift occurring within India's expanding urban middle and upper-middle classes.²³

Sometime within the current decade, India recorded a historic demographic milestone: for the first time in the nation's recorded history, more children began to be born to women in their late twenties than to those in their early twenties.²³ This transition mimics the demographic evolution observed in the United Kingdom in the early 1970s, indicating a maturation of the Indian reproductive timeline.²³ In metropolitan hubs like Delhi, the evidence of delayed motherhood is stark. Census and municipal data from 2024 indicate that the share of births to women aged 30–34 surged dramatically from 9.9% in 2005 to 24.6% in 2024.²⁵ Even more tellingly, births to mothers aged 35 or older more than tripled, rising from 2.7% to 8.9% over the same period.²⁵ Conversely, the share of births to younger women aged 20–24 plummeted from 46.6% down to 27.1%, representing a near 20-percentage-point decline that signals the end of early motherhood as the dominant urban reproductive pattern.²⁵

Biologically, human female fecundity is strictly governed by a finite ovarian reserve, which undergoes a precipitous and irreversible decline after the age of 30, with a sharp acceleration in atresia and degradation after the age of 35.²⁰ This decline is characterized not only by a reduction in oocyte quantity but, more critically, by a severe degradation in oocyte quality, marked by an exponential increase in chromosomal aneuploidies and meiotic spindle abnormalities.²⁶

While delayed motherhood is a highly rational and often necessary socioeconomic response to increased female educational attainment, workforce participation, and the pursuit of financial and emotional stability prior to family building, the rigid physiological reality of human reproduction frequently clashes with these modern socioeconomic timelines.²⁵ Advanced maternal age (defined clinically as  35 years) is not only a primary, independent driver of subfecundity but is also strongly associated with a spectrum of adverse obstetric and maternal outcomes.²⁹ Multivariable logistic regression analyses of Indian data indicate that women experiencing delayed motherhood possess significantly higher adjusted odds (AOR: 1.15) of being underweight or suffering from nutritional deficiencies, alongside an elevated risk for complex, high-risk obstetric interventions.²⁹

A pervasive and dangerous misconception among urban couples is the belief that Assisted Reproductive Technology can entirely mitigate the consequences of age-related fertility decline.²⁶ While ART provides powerful interventions, it cannot reverse intrinsic, age-dependent oocyte degradation, making the biological clock an enduring, unyielding factor in the Indian infertility landscape.²⁶

Endocrine and Metabolic Pathologies: The Ascendancy of PCOS

The clinical profile of the infertile Indian female is undergoing a rapid and alarming evolution. Traditional etiologies of infertility are now increasingly overshadowed by a soaring prevalence of metabolic, endocrine, and inflammatory systemic disorders.

Polycystic Ovary Syndrome (PCOS): A Systemic Metabolic Epidemic

Polycystic Ovary Syndrome (PCOS) has definitively emerged as one of the leading causes of anovulatory infertility in India.⁸ Characterized fundamentally by clinical or biochemical hyperandrogenism, oligo-anovulation (irregular or absent menstrual cycles), and polycystic ovarian morphology (PCOM) visible on transvaginal ultrasound, PCOS is a highly heterogeneous endocrine disorder that profoundly disrupts normal folliculogenesis.⁸

Historically, the pooled prevalence of PCOS among Indian women of reproductive age was estimated at approximately 8.41%.³⁴ However, recent, rigorously designed multicenter epidemiological assessments indicate that the actual contemporary prevalence is vastly higher. A 2024 study conducted in the Delhi National Capital Region (NCR) among young women revealed an astonishing prevalence rate of 17.40%, with prevalence climbing to 23.40% among females aged 20 years and above.³⁴ Globally, PCOS prevalence is reported between 4% and 21%, placing the Indian urban demographic at the absolute highest end of the global spectrum.³²

The diagnosis and classification of PCOS rely heavily on the Rotterdam Criteria, which delineate the syndrome into four distinct phenotypes.³² Phenotype A (the classic, most severe form encompassing hyperandrogenism, anovulation, and PCOM) and Phenotype C (which presents with hyperandrogenism and PCOM, but crucially, maintains regular menstrual cycles) are exceptionally prevalent among Indian women.³²

The pathogenesis of PCOS in the Indian context is heavily intertwined with a genetic predisposition to metabolic dysfunction, specifically rising rates of insulin resistance (IR) and central adiposity.⁸ The South Asian phenotype is inherently predisposed to severe insulin resistance, which induces a state of chronic, compensatory hyperinsulinemia.³³ At the molecular level, elevated circulating insulin acts directly on the insulin receptors of the ovarian theca cells, synergizing with Luteinizing Hormone (LH) to aggressively upregulate the production of ovarian androgens (testosterone and androstenedione).³³ Concurrently, hyperinsulinemia suppresses the hepatic synthesis of sex hormone-binding globulin (SHBG), thereby increasing the bioavailability of free, active testosterone in the systemic circulation.³³

This profoundly altered hormonal milieu—characterized by an elevated LH to Follicle-Stimulating Hormone (FSH) ratio, excessive Gonadotropin-Releasing Hormone (GnRH) pulsatility, and hyperandrogenism—arrests normal follicular development at the pre-antral stage.³³ The physiological outcome is the characteristic accumulation of multiple small, cystic follicles that fail to mature and ovulate, resulting in chronic anovulation and, consequently, severe primary or secondary infertility.³³

The rapid urbanization of dietary habits, the influx of highly processed carbohydrates, and increasingly sedentary occupational routines act as potent, unavoidable environmental triggers, unmasking these underlying genetic susceptibilities to PCOS across the Indian subcontinent.⁸ Furthermore, the metabolic sequelae of PCOS extend far beyond reproductive failure, carrying grave long-term risks for nonalcoholic fatty liver disease, dysglycemia, type 2 diabetes mellitus, cardiovascular disease, and severe psychological depression.³²

Structural and Inflammatory Disorders: The Endometriosis Epidemic

Parallel to the metabolic crisis of PCOS is the silent, progressive epidemic of endometriosis, an inflammatory disorder that severely compromises female reproductive anatomy and embryonic receptivity.

Rising Prevalence and Pathophysiology

Endometriosis is a chronic, estrogen-dependent inflammatory condition defined unequivocally by the presence of endometrial-like glands and stroma outside the uterine cavity, most commonly implanting on the ovaries, fallopian tubes, and the pelvic peritoneum.³⁶ Globally, and specifically in India, the condition affects approximately 10% of women of reproductive age; given India's demographics, this translates to an estimated 42 million afflicted Indian women.³⁷

Clinical data analytics reveal a concerning upward trajectory in the manifestation of this disease. The rate of endometriosis diagnoses increased by a staggering 32% between 2017 and 2024, rising from 24.9 to 32.8 per 10,000 patients.³⁶ The highest diagnosis rates are currently identified in women aged 35 to 49, reflecting both the progressive nature of the disease and the historical delays in achieving a definitive diagnosis.³⁶

Endometriosis drives infertility through a multitude of highly destructive mechanisms. Structurally, the repeated cyclical bleeding of ectopic endometrial lesions induces severe localized inflammation, leading to the formation of dense fibrotic adhesions and scar tissue that can mechanically distort pelvic anatomy and completely occlude the fallopian tubes.³⁸ Biochemically, the disease generates a highly toxic pelvic microenvironment; chronic inflammation, elevated cytokines, and reactive oxygen species negatively impact oocyte quality, impede sperm motility, and interfere with the delicate process of fertilization.³⁸ Furthermore, women with endometriosis frequently exhibit inherent progesterone resistance within their eutopic (normal) endometrium, creating an inhospitable environment that directly impedes successful blastocyst implantation, even when high-quality embryos are generated via IVF.³⁸

The clinical symptomatology of endometriosis is exceptionally burdensome. A large-scale study conducted in South India revealed that nearly 33.3% of afflicted patients report severe dysmenorrhea (painful menstruation), and 28.4% report debilitating dyspareunia (painful intercourse).⁴⁰ The psychosocial toll is profound; women with endometriosis report significant decreases in their overall quality of life, severe financial distress due to ongoing medical care, strained intimate relationships, and deep psychological trauma stemming from the dual burden of chronic pain and infertility.³⁷

Medical management of endometriosis-associated pain and infertility is complex, as the ideal treatment must suppress estradiol sufficiently to starve the ectopic lesions while maintaining enough estrogen to prevent severe hypoestrogenic side effects (such as bone mineral density loss).³⁹ Initial management typically relies on non-steroidal anti-inflammatory drugs (NSAIDs) paired with combined oral contraceptive pills (COCPs) or progestogens.³⁹ Advanced pharmacological interventions include Dienogest (a highly specific 19-nortestosterone derivative), Dydrogesterone, and Elagolix (an oral, non-peptide GnRH antagonist).³⁹ For patients actively seeking conception, aromatase inhibitors are frequently utilized as second-line agents to prevent the peripheral and ovarian conversion of steroid precursors into estrogens.³⁹

Diagnostic Breakthroughs: The Era of Liquid Biopsies

Historically, the definitive diagnosis of endometriosis required invasive laparoscopic surgery coupled with histological confirmation of excised lesions. Because the initial symptoms (pelvic pain, cramping) are highly non-specific and frequently normalized by society, patients experience a profound diagnostic delay averaging between 4 to 11 years from the onset of symptoms.³⁶ By the time of surgical diagnosis, a large proportion of patients present with moderate to severe (Stage III to IV) disease, characterized by irreversible structural damage.⁴²

However, the years 2025 and 2026 have witnessed a true watershed moment in the non-invasive diagnosis of endometriosis, driven by the integration of artificial intelligence and advanced molecular biology. Researchers and clinicians are rapidly validating liquid biopsy techniques that detect specific epigenetic, transcriptomic, and proteomic biomarkers, entirely circumventing the need for surgical intervention.¹⁴

Table 2: Innovations in Non-Invasive Diagnostics for Endometriosis (2025-2026).¹⁴

Diagnostic Modality	Biological Medium	Target Biomarkers / Mechanism	Diagnostic Potential & Status
Salivary Biomarker Test	Saliva	109-miRNA (microRNA) signature analyzed via AI modeling.44	Highly accurate early detection; validated via artificial intelligence.44
cfDNA Methylation Profiling	Peripheral Blood (Plasma)	Cell-free DNA methylation patterns targeting a specific 9-gene molecular signature.44	Identifies epigenetic dysregulation linked to endometriosis; pending broader validation.44
Menstrual Effluent Analysis	Menstrual Blood / Effluent	RNA sequences and specific estrogen levels indicating adhesion process disruption.45	Capitalizes on heavy menstrual bleeding symptoms; avoids invasive pelvic exams.45
Microfluidic Chip Detection	Peripheral Blood	Isolation of circulating endometrial cells via advanced microfluidics.42	Currently undergoing clinical trials (e.g., NCT05749341) to evaluate diagnostic efficiency.42
Multiplex AI Panel	Blood	Analysis of 3 miRNAs, 3 proteins, steroid hormones, BMI, and age.14	Demonstrated 94.4% accuracy and 97.5% specificity; nearing FDA submission in late 2026.14

 

These non-invasive tools promise to revolutionize the management of endometriosis. By enabling early, accurate detection at the primary care level, clinicians can initiate precision-medicine-guided suppression of ectopic lesions years before irreversible fibrotic damage and infertility occur, fundamentally altering the trajectory of the disease for millions of Indian women.¹⁴

Infectious Etiologies: Genital Tuberculosis and Pelvic Inflammatory Disease

While metabolic and inflammatory conditions capture a significant portion of contemporary clinical attention, infectious morbidities—specifically Genital Tuberculosis (GTB) and Pelvic Inflammatory Disease (PID)—remain formidable, albeit often silent, drivers of tubal factor infertility in India.⁴⁶

The Hidden Epidemic of Genital Tuberculosis (GTB)

Genital Tuberculosis is accurately described within the Indian medical community as a "hidden epidemic." While India currently bears the world's highest burden of pulmonary tuberculosis, extrapulmonary manifestations like GTB are grossly underdiagnosed because they are frequently entirely asymptomatic or present with vague symptoms that perfectly mimic other reproductive tract pathologies.¹⁰

Mycobacterium tuberculosis bacilli typically seed the female reproductive tract hematogenously (via the bloodstream) or, less frequently, via the lymphatic system from a primary pulmonary or extra-pulmonary focus.⁴⁷ The infection overwhelmingly targets the fallopian tubes, which are structurally and functionally compromised in 90% to 100% of all GTB cases.⁴⁷ The invasion of the bacilli induces a severe host immune response, leading to the formation of characteristic caseating and non-caseating granulomas.⁴⁷ This intense granulomatous inflammation causes progressive mucosal destruction, dense fibrosis, architectural distortion, and ultimate tubal occlusion, frequently resulting in the formation of fluid-filled (hydrosalpinx) or pus-filled (pyosalpinx) tubal masses.³¹ When the mycobacterial infection invades the uterine cavity, it aggressively destroys the basal layer of the endometrium, causing severe intrauterine adhesions and cavity obliteration—a condition known as Asherman’s syndrome—which renders natural embryo implantation physically impossible.⁴⁷

The epidemiological impact is staggering: GTB is responsible for an estimated 15% to 20% of all infertility cases in high-prevalence Indian demographics, with some localized studies in urban centers suggesting prevalence rates approaching 30% among infertile cohorts.⁴⁷ Infertility itself is the most common presenting symptom, observed in 70% to 80% of affected women, often accompanied by menstrual irregularities (oligomenorrhea, amenorrhea) secondary to endometrial destruction.⁴⁷

Diagnosing GTB represents a profound clinical challenge. Traditional diagnostic methodologies, such as Ziehl-Neelsen smear microscopy and conventional bacterial culture, exhibit notoriously poor sensitivity for paucibacillary genital specimens.⁴⁷ Consequently, contemporary best practices in India now strictly mandate a multimodal diagnostic approach. This includes the utilization of advanced molecular diagnostics—specifically GeneXpert MTB/RIF and multiplex Nucleic Acid Amplification Tests (NAAT/PCR) performed on endometrial biopsies taken during the pre-menstrual phase.⁴⁷ This is frequently paired with diagnostic laparohysteroscopy to visually identify tubercles, caseation, and pelvic adhesions.⁴⁷

While a standard six-month regimen of multi-drug anti-tubercular therapy (ATT) is highly effective at eradicating the active mycobacterial infection, it is essentially powerless to reverse the profound architectural and fibrotic damage already inflicted upon the fallopian tubes and endometrium.⁴⁷ Consequently, even after microbiological cure, the vast majority of these patients require immediate triage to In Vitro Fertilization (IVF) to achieve conception, bypassing the destroyed tubal anatomy entirely.⁴⁷ The increasing incidence of multidrug-resistant tuberculosis (MDR-TB) in India further complicates this landscape, requiring longer, highly toxic drug regimens that exacerbate the risk of permanent organ damage.⁴⁷

Pelvic Inflammatory Disease (PID)

Concurrently, general Pelvic Inflammatory Disease (PID), driven predominantly by ascending sexually transmitted infections (STIs) such as Chlamydia trachomatis and Neisseria gonorrhoeae, continues to rise as a critical public health issue.⁴⁶ Risk factors highly prevalent in the Indian socio-cultural context include early marital age, early sexual debut, high parity, the utilization of unsterile intrauterine contraceptive devices (IUCDs), home deliveries conducted by untrained personnel, and poor menstrual hygiene.⁴⁶

Like GTB, repeated or untreated episodes of PID inflict cumulative, microscopic damage on the delicate ciliated epithelium of the fallopian tubes. This damage severely impairs the tubes' ability to transport the ovum and the embryo, significantly elevating the risks of both permanent tubal factor infertility and life-threatening ectopic pregnancies.⁴ The burden of PID is disproportionately borne by women in younger reproductive age groups, who are often unaware of the early, subtle signs of ascending infection.⁴⁶

The Modern Exposome: Environmental Toxicants and Female Fecundity

Perhaps the most insidious, widespread, and rapidly accelerating contributor to India's declining female fertility is pervasive environmental pollution. The concept of the "exposome"—the totality of environmental, dietary, and chemical exposures an individual faces across their lifespan—has undergone a radical and toxic transformation in India over the past two decades.

Air Pollution and Oxidative Stress

Indian metropolises consistently rank among the most severely polluted urban environments globally, and the reproductive consequences of this atmospheric toxicity are now quantitatively established through rigorous clinical cohort studies.⁹ Chronic maternal exposure to fine particulate matter ( ), nitrogen dioxide ( ), and ozone ( ) has profound, systemic reproductive implications.⁹

Particulate matter of  or smaller easily penetrates the alveolar-capillary barrier of the lungs, entering the systemic circulation and initiating a cascade of severe systemic inflammation and endothelial dysfunction.⁹ A pivotal 2025 clinical study demonstrated a direct, dose-dependent inhibitory effect: for every  increase in ambient  exposure, female fertility potential drops by an estimated 12%.⁵³ These airborne pollutants generate massive quantities of reactive oxygen species (ROS) within the highly sensitive ovarian microenvironment.⁹ This severe oxidative stress triggers the apoptosis (programmed cell death) of ovarian granulosa cells, which are essential for nurturing the developing oocyte.⁹

Clinically, this sustained oxidative damage manifests as a prematurely diminished ovarian reserve, objectively reflected in significantly lower circulating levels of Anti-Müllerian Hormone (AMH) and a reduced Antral Follicle Count (AFC) upon ultrasound examination.⁹ Furthermore, in the context of advanced fertility treatments, acute exposure to high levels of particulate matter in the days immediately preceding an embryo transfer during an IVF cycle is associated with significantly higher miscarriage rates and lower overall clinical pregnancy rates, indicating that air pollution compromises both oocyte competence and immediate endometrial receptivity.⁹

Endocrine-Disrupting Chemicals (EDCs)

Endocrine-Disrupting Chemicals (EDCs) are synthetic, human-made substances that are ubiquitous in Indian soil, municipal water systems, agricultural runoff, and everyday consumer products.⁹ Chemicals such as Bisphenol A (BPA), various phthalates, per- and polyfluoroalkyl substances (PFAS), polychlorinated biphenyls (PCBs), and heavy metals (lead, cadmium, mercury) severely disrupt normal physiological hormonal homeostasis.⁵⁴

EDCs operate through highly insidious molecular mechanisms: they structurally mimic, competitively block, or alter the endogenous synthesis, transport, and metabolism of natural sex hormones (estrogens and androgens).⁵⁵ This chemical interference wreaks havoc on the highly sensitive Hypothalamic-Pituitary-Gonadal (HPG) axis.⁵⁴

●     Bisphenol A (BPA): Ubiquitous in polycarbonate water bottles, food storage containers, and the epoxy linings of canned foods, BPA acts as a potent estrogen agonist or antagonist.⁵⁵ Elevated serum BPA levels are strongly associated with a lower ovarian reserve, reduced antral follicle counts, and are heavily implicated in the pathogenesis and exacerbation of PCOS.⁵⁵

●     Phthalates (PAEs): Found extensively in food packaging, cosmetics, lotions, synthetic fragrances, and personal care products (PCPs), phthalates severely interfere with the feedback mechanisms of the HPG axis.⁵⁵ High urinary concentrations of phthalate metabolites are linked to the onset of early puberty, severe HPG axis dysregulation, and a significantly elevated risk of developing endometriosis and premature ovarian insufficiency (POI).⁵⁵

●     Heavy Metals: Metals such as Lead (Pb), Mercury (Hg), and Cadmium (Cd) are frequently found in contaminated groundwater and loosely regulated cosmetics (including skin-lightening products popular in the subcontinent).⁵⁵ Lead exposure causes delayed pubertal development and stimulates apoptotic pathways in reproductive tissues.⁵⁵ Cadmium is an established reproductive toxicant associated with abnormal menstrual cycles, severe dysmenorrhea, decreased folliculogenesis, and absolute sterility.⁵⁵

Interestingly, rapid metabolic changes in women, particularly massive weight loss following bariatric surgery, can inadvertently and transiently increase circulating levels of these lipophilic toxicants.⁹ Because EDCs are heavily stored in adipose (fat) tissue, rapid fat loss mobilizes these chemicals directly into the bloodstream, acutely bathing the ovaries and developing follicles in highly concentrated toxicants, thereby amplifying reproductive vulnerability during the exact period a woman might be attempting to conceive.⁹

The Microplastic Threat: Direct Intrusion into the Ovarian Microenvironment

A ground-breaking, paradigm-shifting discovery in late 2024 and 2025 radically altered the scientific understanding of environmental reproductive toxicity: the detection of microplastics (MPs) directly within human ovarian follicular fluid and human placental tissue.⁵⁹ India is currently recognized as the world's largest plastic polluter, releasing an estimated 9.3 million tonnes annually, making this discovery highly relevant to the Indian demographic.⁶¹

Follicular fluid is the critical, highly regulated biochemical matrix that surrounds the egg, providing essential nutrients, hormones, and signaling molecules necessary for optimal oocyte development and maturation.⁵⁹ The presence of microplastics in this sacred biological microenvironment confirms beyond doubt that plastic particulates—ingested through food, water, or inhaled from the air—can cross rigorous cellular barriers and permanently accumulate in deep reproductive organs.⁵⁹

In vitro mechanistic studies have confirmed that microplastic beads—particularly those composed of polyethylene (PE) and polymethyl methacrylate (PMMA)—can physically adhere to or actively penetrate the zona pellucida (the outer protective shell of the egg).⁶² This physical and chemical intrusion induces profound oxidative injury, drastically hinders normal oocyte maturation, reduces endogenous estradiol levels, and exponentially elevates the risk of spontaneous abortions and early embryonic arrest.⁹ Furthermore, microplastics act as highly efficient "Trojan horses" or vectors, leaching massive concentrations of bound EDCs (like BPA and phthalates) directly onto the gametes, delivering a concentrated, localized dose of endocrine disruptors right at the site of fertilization.⁹

Lifestyle, Nutritional Deficits, and Psychosocial Stress

Beyond chemical and atmospheric pollution, fundamental shifts in urban Indian lifestyles—specifically relating to diet and chronic psychological stress—are exerting a profound dampening effect on female reproductive potential.

Dietary Transformations: The Impact of Ultra-Processed Foods

The rapid, large-scale integration of ultra-processed foods (UPFs) into the daily Indian diet represents a severe and systemic threat to national reproductive health. UPFs, classified under the NOVA system, are industrially formulated, hyper-palatable products replete with refined sugars, hydrogenated trans fats, artificial emulsifiers, and chemical preservatives, while remaining almost entirely devoid of essential dietary fiber, crucial micronutrients, and protective antioxidants.⁶⁴

Recent large-scale, cross-sectional analyses of reproductive-aged women utilizing data models akin to the National Health and Nutrition Examination Survey (NHANES) have drawn direct, undeniable correlations between high UPF intake and clinical female infertility.⁶⁵ Women categorized in the highest quartile or tertile of daily UPF consumption demonstrate significantly elevated odds of experiencing self-reported infertility compared to their peers in the lowest quartile.⁶⁵ This upward trend in infertility risk becomes notably severe when UPF intake exceeds 40.8% of total daily energy consumption.⁶⁹

The pathophysiological mechanisms linking UPF consumption to diminished female fecundity are extensive and multifaceted. Firstly, diets disproportionately high in UPFs induce rapid, sustained glycemic spikes, driving states of chronic hyperinsulinemia.⁷⁰ As established, elevated insulin aggressively exacerbates the hormonal imbalances and ovarian hyperandrogenism inherent in PCOS, effectively halting ovulation.³³ Secondly, the chemical additives and poor lipid profiles of UPFs foster a state of systemic, low-grade inflammation throughout the body, creating an internal environment that is fundamentally hostile to optimal oocyte maturation and subsequent endometrial receptivity.⁶⁸

Furthermore, groundbreaking 2026 data evaluating human embryo morphokinetics from the Generation R Study reveals that high maternal and paternal UPF consumption around the time of conception is associated with significantly slower cellular cleavage rates in early embryos.⁶⁴ Notably, embryos generated from high-UPF parents exhibit significantly smaller embryonic yolk sacs—a structure absolutely critical for early embryonic nutrition and hematopoietic development.⁶⁴ This indicates that poor maternal nutrition does not merely prevent conception; it actively compromises early embryogenesis and the intrinsic viability of the implantation process itself.⁶⁴ Conversely, transitioning away from UPFs toward nutrient-dense, anti-inflammatory regimens—such as adherence to the Mediterranean diet or traditional Indian diets rich in complex carbohydrates and polyunsaturated fatty acids—is proven to mitigate these reproductive risks, although these dietary benefits are heavily modulated by the patient's baseline body mass index (BMI) and total visceral adiposity.⁶⁶

Chronic Psychosocial Stress and Neuroendocrine Disruption

The modern urban Indian workforce environment is characterized by relentless high-pressure demands, prolonged commutes, intense financial insecurity, and immense, unremitting psychosocial stress, all of which act as potent, biologically programmed suppressors of human fertility.⁸

When the brain perceives chronic psychological stress, it rapidly activates the sympathetic-adrenal-medullary (SAM) axis and the hypothalamic-pituitary-adrenal (HPA) axis, resulting in chronically elevated, non-cyclical levels of circulating cortisol and corticotrophin-releasing hormone (CRH).⁸ These stress hormones exert a direct, powerful inhibitory effect on the hypothalamic-pituitary-ovarian (HPO) axis, which governs the entire reproductive cycle.⁸

Specifically, elevated cortisol profoundly suppresses the normal, pulsatile release of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus.⁷⁴ This suppression is mediated significantly through the kisspeptinergic system—a highly specialized network of neurons located in the arcuate nucleus (ARC) and the rostral periventricular region of the third ventricle (RP3V) of the hypothalamus.⁷⁴ The kisspeptin system acts as the central neurological gatekeeper, integrating metabolic status (via leptin and insulin), environmental cues, and stress signals to regulate reproductive function.⁷⁴

Chronic stress downregulates kisspeptin signaling, which in turn severely dampens the amplitude and frequency of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) pulses secreted from the anterior pituitary gland.⁷³ The clinical outcome of this neuroendocrine cascade is stress-induced functional hypothalamic amenorrhea, erratic and unpredictable folliculogenesis, and chronic anovulation.⁷⁴ Furthermore, chronic stress exacerbates oxidative damage within the ovarian microenvironment itself, accelerating the natural decline of the ovarian reserve and leading directly to poorer clinical outcomes in IVF cycles due to compromised oocyte competence and failed fertilization.⁷²

The Prolonged Reproductive Shadow of COVID-19

While the acute, life-threatening phases of the global COVID-19 pandemic have largely subsided, the insidious long-term sequelae—commonly referred to as Long COVID—are exerting a prolonged, complex toll on female reproductive health and menstrual regularity in India.⁷⁶

The SARS-CoV-2 virus gains intracellular entry into human tissues primarily through the angiotensin-converting enzyme 2 (ACE2) receptor, with the transmembrane protease serine 2 (TMPRSS2) facilitating essential viral spike protein priming.⁷⁷ The ACE2 receptor is highly expressed throughout the human female reproductive tract, particularly in the ovaries.⁷⁷ ACE2 expression is dynamically regulated and is especially abundant during the secretory (luteal) phase of the menstrual cycle, where it plays a critical role in regulating follicular development, ovulation, and essential luteal angiogenesis.⁷⁷ Alternative viral entry routes in reproductive tissues include Basigin (CD147 or EMMPRIN), which is heavily expressed in the uterus and is linked to interactions between ovarian and endometrial tissues.⁷⁷

Viral binding to the ACE2 receptor profoundly disrupts the local renin-angiotensin system (RAS) by causing a toxic accumulation of Angiotensin I and II while simultaneously decreasing the vital levels of Angiotensin 1-7.⁷⁷ Angiotensin 1-7 is a critical peptide for reproductive success; it supports the mechanics of ovulation, maintains the structural integrity and thickness of the endometrium during the ovulatory phase, and facilitates healthy, early placental development.⁷⁷ The systemic depletion of this vital peptide, coupled with severe, virus-induced systemic inflammatory responses (such as macrophage activation and cytokine storms), directly impairs normal ovarian steroidogenesis and profoundly diminishes endometrial receptivity.⁷⁷

Additionally, the virus physically alters the delicate balance of the hypothalamic-pituitary axis, causing downstream abnormalities in the physiological release of GnRH, LH, and FSH.⁷⁷ Longitudinal clinical studies of Indian women post-COVID-19 infection reveal alarming data: the incidence of severe menstrual cycle irregularities—including significantly altered cycle lengths, increased severity of dysmenorrhea (headaches, muscle pain during bleeding), and highly abnormal bleeding patterns—nearly doubled from pre-infection baselines, jumping from 11.1% to 20.4% in specific cohorts.⁷⁷ This lasting physiological disruption underscores the absolute necessity of continuous, sex-specific surveillance of women suffering from Long COVID to mitigate potentially permanent fertility impairment.⁷⁸

Evolution and Efficacy of Assisted Reproductive Technology (ART)

As the multifaceted drivers of female infertility intensify across the subcontinent, India has witnessed explosive, unprecedented growth in the Assisted Reproductive Technology (ART) market. Valued at approximately USD 2.35 billion in 2024, the Indian in-vitro fertilization services market is projected to expand at a robust compound annual growth rate (CAGR) of between 7.9% and 16.23%, with projections indicating valuations will exceed USD 5.03 billion by 2034.¹¹ This massive market expansion is fueled by rising domestic demand driven by the aforementioned pathologies, increasing societal acceptance of fertility treatments, a massive influx of international medical tourism seeking world-class yet cost-effective treatments, and rapid, continuous clinical advancements in embryology.¹¹

Clinical Efficacy, Benchmarks, and Success Rates

The clinical success of IVF in India has improved significantly in recent years due to highly optimized ovarian stimulation protocols, refined gamete cryopreservation (vitrification) techniques, and vastly superior laboratory quality control environments.⁸² The Indian Society for Assisted Reproduction (ISAR) has published rigorous Good Clinical Practice Recommendations (GCPR) that benchmark success for ART laboratories across the country.⁸⁵ These guidelines mandate achieving an oocyte morphological survival rate post-thaw of 85% (increasing to an exceptional 95% for donors under 30 years of age) and a blastocyst survival rate of 95%.⁸⁵

Furthermore, ISAR guidelines heavily favor the utilization of GnRH antagonist protocols over traditional long agonist protocols for patients with a normal ovarian reserve, as this modern approach results in fewer days of hormonal stimulation, significantly lower required dosages of gonadotrophins, and a drastically reduced incidence of the potentially fatal Ovarian Hyperstimulation Syndrome (OHSS).⁸⁵ Individualized Luteal Phase Support (LPS) using progesterone or hCG is also universally mandated to combat the luteal-phase deficiency inherent in stimulated ART cycles.⁸⁵

However, despite these advanced protocols, IVF success remains overwhelmingly and immutably age-dependent, perfectly illustrating the biological limits of current medical technology.⁸²

Table 3: Stratification of Average IVF Success Rates in India by Maternal Age Cohort (Compiled from ICMR, ISAR registries, and leading national fertility centers, 2025).⁸³

Maternal Age Cohort	Average IVF Clinical Pregnancy Rate (per cycle)	Primary Clinical Determinants of Success or Failure
Under 35 Years	50% – 65%	Characterized by an optimal ovarian reserve, high euploidy (chromosomally normal) rates, and a highly receptive endometrium. Single Embryo Transfer (SET) is typically recommended.27
35 – 37 Years	45% – 55%	Marks the beginning of a significant increase in chromosomal aneuploidy and a moderate drop in total ovarian reserve.27
38 – 40 Years	31% – 35%	Exhibits a severe decline in oocyte quality and mitochondrial function; requires increased utilization of PGT-A to identify viable embryos.83
Over 40 Years	11% – 22%	Characterized by a near-total depletion of euploid oocytes; patients in this cohort frequently require triage to third-party reproduction (donor oocytes).27
Donor Oocyte Cycles	65% – 80%	Successfully bypasses all age-related oocyte degradation by utilizing high-quality gametes harvested from rigorously screened young donors (typically <30 years old).84

 

Frozen Embryo Transfers (FET) have definitively become the dominant clinical paradigm in modern Indian IVF, boasting impressive success rates of 50% to 70% in younger cohorts.⁸² By temporally separating the intense process of ovarian stimulation from the delicate embryo transfer, FET allows the patient's endometrium to fully recover from the supraphysiological hormone levels generated during the stimulation phase.⁸² This fosters a much more receptive, natural uterine environment for implantation, significantly increasing live birth rates while simultaneously eliminating the risk of late-onset OHSS.⁸²

Technological Frontiers: Artificial Intelligence and Epigenetics

The absolute vanguard of ART in India in 2026 is defined by the deep, systemic integration of Artificial Intelligence (AI) and complex machine learning algorithms into the embryology laboratory.¹³ Traditionally, embryo selection—the most critical step in an IVF cycle—relied entirely on the subjective, morphological assessment of embryologists viewing embryos under a microscope at static time points.⁸⁹ This manual process is inherently prone to human error, cognitive fatigue, and severe inter-observer variability.⁸⁹

Today, advanced computer vision and deep learning algorithms continuously process vast amounts of morphokinetic data derived from time-lapse incubators.⁸⁸ These AI systems objectively evaluate the exact timing of cellular cleavage events, predicting embryo ploidy (chromosomal normalcy) and the statistical likelihood of successful implantation with unprecedented accuracy.⁸⁸

AI is further revolutionizing the clinical management of the patient prior to egg retrieval. Award-winning Indian clinics have deployed AI-based Dosage Calculators that analyze massive historical datasets to intelligently optimize daily gonadotropin (HMG) doses for individual patients.¹³ This data-driven approach maximizes the yield of mature, competent eggs while strictly minimizing the risk of severe OHSS, a life-threatening complication.¹³ Additionally, AI is being heavily deployed alongside non-invasive preimplantation genetic testing (niPGT).⁹⁰ Instead of subjecting a fragile embryo to an invasive trophectoderm biopsy (which carries inherent risks of cellular damage), niPGT evaluates the cell-free DNA naturally released by the growing embryo directly into the surrounding culture medium to accurately assess chromosomal ploidy.⁹⁰ Advanced, multimodal AI fusion models are also actively evaluating ultrasound radiomics and systemic immune-infiltration factors to pinpoint the exact window of endometrial receptivity for each specific patient, successfully resolving the embryo-endometrial asynchrony that historically caused roughly 30% of all unexplained implantation failures.⁹¹

Simultaneously, breakthrough molecular research into reproductive epigenetics—specifically focusing on DNA methylation, histone modification, and non-coding RNAs—is shedding critical light on exactly how environmental pollutants (EDCs, PM2.5) program transgenerational infertility at the chromosomal level.⁴¹ Emerging, highly targeted therapies aimed at modulating these specific epigenetic marks hold immense future promise for chemically reversing environmentally induced gamete degradation and completely restoring fertility potential.⁴¹

Socio-Legal Framework: Navigating the ART and Surrogacy Acts of 2021

The exponential proliferation of an estimated 40,000 largely unregulated ART clinics across India created a highly problematic "reproductive bazaar".¹⁵ For over two decades, this under-regulated sector was fraught with egregious ethical transgressions, the blatant commercial exploitation of impoverished, lower-caste women acting as egg donors and surrogate mothers, and highly opaque, unethical medical practices designed to maximize clinic profit margins.¹⁵ In a sweeping response to these deeply entrenched issues, the Indian Parliament enacted two landmark pieces of legislation: the Assisted Reproductive Technology (Regulation) Act, 2021, and the Surrogacy (Regulation) Act, 2021.¹⁶

These comprehensive legislative frameworks were designed to forcefully institutionalize rigorous safety protocols, mandate the strict registration and monitoring of all clinics under the newly formed National ART and Surrogacy Registry, and transition the nation entirely away from commercial surrogacy to a strictly altruistic surrogacy model.¹⁵ However, while the Acts successfully achieved their primary goal of curtailing blatant commercial exploitation, their rigid, conservative structure has generated profound, unintended socio-clinical consequences that actively threaten the stability of the entire fertility sector.

Primarily, the legislation legally enforces a strictly heteronormative, highly patriarchal model of family building.¹⁵ By explicitly restricting ART and surrogacy access exclusively to heterosexual married couples (and, under highly specific and narrow conditions, certain legally divorced or widowed single women), the Act actively and legally disenfranchises single men, unmarried cohabiting (live-in) couples, and the entirety of the LGBTQIA+ community.¹⁵ This overt, legislative exclusion directly contradicts emerging global paradigms of reproductive justice, bodily autonomy, and equal constitutional rights, drawing severe criticism from sociologists, bioethicists, and legal scholars.¹⁵

Furthermore, the operational and economic dynamics mandated by the Act have catalyzed a severe, ongoing supply-chain crisis within the IVF clinical ecosystem. By strictly prohibiting any form of direct financial compensation or remuneration for gamete (egg and sperm) donors—allowing clinics only to cover basic, out-of-pocket medical expenses and mandatory insurance—the primary economic incentive for egg donation has entirely evaporated overnight.¹⁵

This well-intentioned but economically naive push for pure altruism has resulted in an acute, crippling scarcity of donor gametes across the country.¹⁵ This shortage has severely elongated wait times for the thousands of Indian women facing premature ovarian insufficiency (POI), severe endometriosis, or advanced maternal age who absolutely depend on donor oocyte IVF cycles to achieve pregnancy.¹⁵ Consequently, sociologists, legal experts, and frontline clinicians warn that this intense regulatory friction is highly likely to inadvertently spawn a dangerous black market for gametes.¹⁵ In such a clandestine market, vulnerable, economically disadvantaged women would be subjected to unsafe, unmonitored, and aggressive ovarian stimulation protocols entirely outside the purview and protection of the National Registry, ultimately and tragically subverting the very protective intent of the original legislation.¹⁵

Conclusion and Strategic Imperatives

The rising tide of female infertility in India represents a multifaceted, highly complex public health crisis that transcends basic demographic transitions. While the historic decline of the national Total Fertility Rate below replacement levels undeniably signals the maturation of the Indian society, the concurrent, explosive rise in involuntary childlessness reflects a profound, systemic failure to protect the delicate human reproductive ecology.¹ Delayed motherhood, primarily driven by necessary and positive socioeconomic evolution, inevitably collides with intractable biological timelines.²⁴ This clash underscores the urgent, immediate need for nationwide, proactive fertility preservation awareness campaigns and routine, early Anti-Müllerian Hormone (AMH) screening for young women to empower informed reproductive choices.²⁶

However, advancing maternal age is only a single variable in a highly complex pathological equation. The unprecedented, global-leading escalation of systemic metabolic disorders like PCOS, the tissue-destroying inflammatory devastation of endometriosis, and the silent, highly destructive scourge of Genital Tuberculosis require an immediate paradigm shift in specialized clinical attention.¹⁰ Specifically, GTB must be aggressively destigmatized, and routine, high-sensitivity molecular screening (PCR) for all infertility patients must be formally integrated into the National Tuberculosis Elimination Programme (NTEP).¹⁰ Similarly, the advent of AI-driven, non-invasive liquid biopsies for the early detection of endometriosis must be rapidly scaled, commercialized, and deployed at the primary care level to eradicate the decade-long diagnostic delays that currently condemn millions of women to irreversible tubal and ovarian damage.¹⁴

Crucially, the medical community, environmental scientists, and national policymakers must jointly confront the devastating, quantified impact of the modern Indian exposome. The pervasive, largely unregulated infiltration of ultra-processed foods into the daily diet, the crushing reality of chronic psychosocial and occupational stress, and the invisible bombardment by endocrine-disrupting chemicals—culminating in the alarming, dystopian discovery of microplastics actively penetrating the ovarian microenvironment—indicate unequivocally that female infertility is increasingly an environmentally mediated pathology.⁹ Addressing this requires robust, uncompromising public health interventions: strictly regulating the presence of EDCs in personal care products and food packaging, aggressively curbing urban vehicular and industrial air pollution, and actively promoting nutrient-dense, anti-inflammatory dietary paradigms at the population level.⁵⁵

Finally, as Assisted Reproductive Technology becomes the necessary, unavoidable recourse for millions of Indian citizens attempting to build families, the rigid legal infrastructure governing it must rapidly evolve. The ART (Regulation) Act of 2021 must be critically amended to align with modern principles of reproductive justice, ensuring equitable, unfettered access to fertility treatments for all demographics, regardless of marital status, gender identity, or sexual orientation.¹⁵ Concurrently, lawmakers must develop pragmatic, highly regulated frameworks that safely and legally compensate gamete donors, thereby ensuring a safe, transparent, and stable gamete supply chain without fostering exploitation.¹⁵ Only through a holistic, fiercely integrated synthesis of advanced precision medicine, aggressive environmental protection, targeted nutritional reform, and inclusive, scientifically grounded public policy can India hope to successfully mitigate this profound and deepening reproductive health crisis.

REFERENCES:

1.    Total Fertility Rate Over Two Decades in India: Trend Analysis from a National Survey, accessed on April 6, 2026, https://pubmed.ncbi.nlm.nih.gov/41793333/

2.    Fertility Rate in India - Explained Pointwise - ForumIAS Blog, accessed on April 6, 2026, https://forumias.com/blog/fertility-rate-in-india-explained-pointwise/

3.    Revised India Insight - SWOP 2025.docx, accessed on April 6, 2026, https://asiapacific.unfpa.org/sites/default/files/pub-pdf/2025-06/India%20Insight%20SOWP%202025.pdf

4.    Burden of Infertility, Its Risk Factors, Perceptions and Challenges Faced by Women of Peri-urban Community from Ahmedabad City: Mixed Method Study - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11482390/

5.    Primary and secondary infertility in India: a systematic review and meta-analysis - PubMed, accessed on April 6, 2026, https://pubmed.ncbi.nlm.nih.gov/41664092/

6.    Surging trends of infertility and its behavioural determinants in India - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10368286/

7.    Primary and secondary infertility in India: a systematic review and meta-analysis - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12983635/

8.    Infertility in India - INSIGHTS IAS, accessed on April 6, 2026, https://www.insightsonindia.com/2026/02/06/infertility-in-india/

9.    Environmental Pollution, Endocrine Disruptors, and Metabolic Status: Impact on Female Fertility—A Narrative Review - MDPI, accessed on April 6, 2026, https://www.mdpi.com/2673-3897/6/4/37

10.  Unveiling Genital Tuberculosis: India's hidden Infertility Epidemic, accessed on April 6, 2026, https://njcmindia.com/index.php/file/article/view/4983

11.  India In Vitro Fertilization Market Size, Price, Trends | CAGR Of 7.9% - Nova One Advisor, accessed on April 6, 2026, https://www.novaoneadvisor.com/report/india-in-vitro-fertilization-market

12.  India IVF SERVICES Market Size, Trends, Share 2034 - CMI, accessed on April 6, 2026, https://www.custommarketinsights.com/report/india-ivf-services-market/

13.  Can AI Improve IVF Success Rates? Let's find out - Cityscope Media, accessed on April 6, 2026, https://www.cityscope.media/everywhere/article/can-ai-improve-ivf-success-rates-lets-find-out

14.  Non-invasive diagnostics in endometriosis: at the cusp of a turning point, accessed on April 6, 2026, https://www.pharmaceutical-technology.com/features/non-invasive-diagnostics-in-endometriosis-at-the-cusp-of-a-turning-point/

15.  Reproductive resistance, law, and informality: a critique of the Indian ..., accessed on April 6, 2026, https://www.tandfonline.com/doi/full/10.1080/09589236.2025.2490844

16.  A Critical Analysis of the Assisted Reproductive Technology (Regulation) Act 2021, accessed on April 6, 2026, https://www.researchgate.net/publication/389541451_A_Critical_Analysis_of_the_Assisted_Reproductive_Technology_Regulation_Act_2021

17.  Voices from Health Care Providers: Assessing the Impact of the Indian Assisted Reproductive Technology (Regulation) Act, 2021 on the Practice of IVF in India - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10492714/

18.  Economic Survey 2025-26 Statistical Appendix Table 8.18: Total Fertility Rate (Children per women) across states and U - Union Budget, accessed on April 6, 2026, https://www.indiabudget.gov.in/economicsurvey/doc/stat/tab8.18.pdf

19.  Infertility Burden Across Indian States: Insights from a Nationally Representative Survey Conducted During 2019–21 - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10757690/

20.  Why is Infertility Rising in India? Lifestyle, Environment & Delay in Parenthood, accessed on April 6, 2026, https://hegdefertility.com/blog/why-is-infertility-rising-in-india-lifestyle-environment-delay-in-parenthood/

21.  (PDF) Prevalence and Potential Determinants of Primary Infertility in India: Evidence from Indian Demographic Health Survey - ResearchGate, accessed on April 6, 2026, https://www.researchgate.net/publication/343924912_Prevalence_and_Potential_Determinants_of_Primary_Infertility_in_India_Evidence_from_Indian_Demographic_Health_Survey

22.  Addressing Prevalence of Infertility and Its Implications: With Special Reference to India, accessed on April 6, 2026, https://isaconf.confex.com/isaconf/forum2025/meetingapp.cgi/Paper/160664

23.  The baby boom years | The Big Shift | Data For India, accessed on April 6, 2026, https://www.dataforindia.com/the-baby-boom-years/

24.  Mother's age at childbirth - Data For India, accessed on April 6, 2026, https://www.dataforindia.com/mother-age-childbirth/

25.  Careers before cradles: Delhi women having children in their 30s - The Times of India, accessed on April 6, 2026, https://timesofindia.indiatimes.com/city/delhi/careers-before-cradles-delhi-women-having-children-in-their-30s/articleshow/127789094.cms

26.  India's fertility decline: How lifestyle and environmental factors are reshaping reproductive health, accessed on April 6, 2026, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/indias-fertility-decline-how-lifestyle-and-environmental-factors-are-reshaping-reproductive-health/articleshow/125056987.cms

27.  IVF Success Rates in India by Age and Embryo Count, accessed on April 6, 2026, https://www.indiraivf.com/blog/ivf-success-rates-by-age-and-number-of-embryos

28.  February 2026: What's New from the Fertility and Sterility Family of Journals - ASRM, accessed on April 6, 2026, https://www.asrm.org/news-and-events/asrm-news/latest-news/February-2026-whats-new-from-fertility-and-sterility2/

29.  Delayed motherhood and maternal health risks in India: findings from a generalized linear model analysis - Frontiers, accessed on April 6, 2026, https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2026.1769597/full

30.  Exploring the shifting landscape of delayed motherhood in India: a comprehensive analysis using joinpoint and age-period-cohort analysis - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12628530/

31.  Prevalence, Types and Contributing Factors of Female Infertility at Orotta National Referral Maternity Hospital, Eritrea: A Cross-Sectional Study - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12728234/

32.  High PCOS prevalence reported in India | Contemporary OB/GYN, accessed on April 6, 2026, https://www.contemporaryobgyn.net/view/high-pcos-prevalence-reported-in-india

33.  Polycystic Ovary Syndrome Among Indian Women - Research Communities, accessed on April 6, 2026, https://communities.springernature.com/posts/polycystic-ovary-syndrome-among-indian-women

34.  Polycystic Ovary Syndrome prevalence and associated ... - PMC - NIH, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12039125/

35.  Prevalence of Polycystic Ovary Syndrome (PCOS) and Its Associated Risk Factors among Medical Students in Two Countries - MDPI, accessed on April 6, 2026, https://www.mdpi.com/1660-4601/21/9/1165

36.  Endometriosis Rates Increasing Across All Ages, Most Common in Women 35–49, accessed on April 6, 2026, https://www.epicresearch.org/articles/endometriosis-rates-increasing-across-all-ages-most-common-in-women-35-49

37.  Experiences of women with endometriosis & their partners in India: Findings from a qualitative study - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12826376/

38.  Endometriosis: Future Biological Perspectives for Diagnosis and Treatment - MDPI, accessed on April 6, 2026, https://www.mdpi.com/1422-0067/25/22/12242

39.  Recent Trends in Medical Management of Endometriosis - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11693626/

40.  (PDF) Prevalence, Surgical, and Medical Management of Patients with Endometriosis amongst Indian Women - ResearchGate, accessed on April 6, 2026, https://www.researchgate.net/publication/377370115_Prevalence_Surgical_and_Medical_Management_of_Patients_with_Endometriosis_amongst_Indian_Women

41.  The role of epigenetics in women's reproductive health: the impact of environmental factors, accessed on April 6, 2026, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1399757/full

42.  Study Details | NCT05749341 | A Liquid Biopsy Diagnostic Techniques for Endometriosis, accessed on April 6, 2026, https://clinicaltrials.gov/study/NCT05749341

43.  Diagnostic Accuracy of Liquid Biomarkers for the Non-Invasive Diagnosis of Endometrial Cancer: A Systematic Review and Meta-Analysis - MDPI, accessed on April 6, 2026, https://www.mdpi.com/2072-6694/14/19/4666

44.  Non-Invasive Methods for Early Diagnosis of Endometriosis—A Comprehensive Narrative Literature Review - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12732459/

45.  Innovative Advances in Non-Invasive Endometriosis Diagnosis, accessed on April 6, 2026, https://endoexcellencecenter.com/innovative-advances-in-non-invasive-endometriosis-diagnosis/

46.  A cross sectional study to know the clinical characteristics and risk factors of patients with pelvic inflammatory disease in th - International Journal of Gynaecology and Obstetrics Research, accessed on April 6, 2026, https://www.gynaecologyjournal.in/assets/archives/2025/vol7issue2/7013.pdf

47.  Unveiling Genital Tuberculosis: India's Hidden Infertility Epidemic, accessed on April 6, 2026, https://www.njcmindia.com/index.php/file/article/download/4983/2178/18521

48.  Comprehensive Review of Genital Tuberculosis: Epidemiological Patterns, Causal Agents, Diagnostic Strategies, Symptomatology and Fertility Consequences - PubMed, accessed on April 6, 2026, https://pubmed.ncbi.nlm.nih.gov/41162731/

49.  She couldn't conceive despite IVF and good test results: How doctors found a silent and overlooked TB - The Indian Express, accessed on April 6, 2026, https://indianexpress.com/article/health-wellness/ivf-good-test-results-how-doctors-found-a-silent-and-overlooked-tb-10601761/

50.  Study of genital tuberculosis among infertile women at tertiary care centre, accessed on April 6, 2026, https://www.ijrcog.org/index.php/ijrcog/article/view/15189

51.  Detection of genital tuberculosis among women with infertility using best clinical practices in India: An implementation study, accessed on April 6, 2026, https://www.hopkinsmedicine.org/infectious-diseases/research/publications/2021/101016jijtb202008003

52.  Infectious pelvic inflammatory disease and In-Vitro fertilization: A review of social landscape and community perceptions | Placenta and Reproductive Medicine, accessed on April 6, 2026, https://www.hksmp.com/journals/prm/article/view/885

53.  Air pollution and fertility potential: evidence from employed women in China - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12487350/

54.  Endocrine-Disrupting Chemicals and Male Infertility: Mechanisms, Risks, and Regulatory Challenges - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12565704/

55.  Role of personal care products as endocrine disruptors ... - Frontiers, accessed on April 6, 2026, https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2025.1514060/full

56.  Endocrine Disruptors | National Institute of Environmental Health Sciences, accessed on April 6, 2026, https://www.niehs.nih.gov/health/topics/agents/endocrine

57.  (PDF) Environmental contaminants and endocrine disrupting chemicals in female infertility: a systematic review - ResearchGate, accessed on April 6, 2026, https://www.researchgate.net/publication/400176476_Environmental_contaminants_and_endocrine_disrupting_chemicals_in_female_infertility_a_systematic_review

58.  Multiple Studies Link Adverse Effects on Female Reproductive Health with Endocrine Disrupting Chemical Exposure - Beyond Pesticides Daily News Blog, accessed on April 6, 2026, https://beyondpesticides.org/dailynewsblog/2025/01/multiple-studies-link-assault-on-female-reproductive-health-with-endocrine-disrupting-chemical-exposure/

59.  Microplastics found in human ovary follicular fluid for the first time - The Guardian, accessed on April 6, 2026, https://www.theguardian.com/society/2025/apr/19/microplastics-human-ovary-follicular-fluid

60.  Microplastics and Human Fertility - Geneva Policy Outlook, accessed on April 6, 2026, https://www.genevapolicyoutlook.ch/microplastics-and-human-fertility/

61.  Microplastic pollution in India-Evidence of major health concern, accessed on April 6, 2026, https://wjarr.com/index.php/content/microplastic-pollution-india-evidence-major-health-concern

62.  Characterization of microplastics in human follicular fluid and assessment of their potential impact on mouse oocyte maturation in vitro - PubMed, accessed on April 6, 2026, https://pubmed.ncbi.nlm.nih.gov/39904258/

63.  Endocrine disruptors in plastic waste: a new public health threat - Legacy IAS Academy, accessed on April 6, 2026, https://www.legacyias.com/endocrine-disruptors-in-plastic-waste-a-new-public-health-threat/

64.  Ultra-processed foods are linked to reduced fertility and embryonic development First study to look at combined impact of diet in both men and women - Focus on Reproduction, accessed on April 6, 2026, https://www.focusonreproduction.eu/press-releases/ultra-processed-foods-are-linked-to-reduced-fertility-and-embryonic-developmentfirst-study-to-look-at-combined-impact-of-diet-in-both-men-and-women/

65.  Consumption of ultra-processed foods and female infertility: a cross-sectional study, accessed on April 6, 2026, https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1597910/full

66.  Consumption of ultra-processed foods and female infertility: a cross-sectional study - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12256463/

67.  Consumption of ultra-processed foods and female infertility: a cross-sectional study, accessed on April 6, 2026, https://pubmed.ncbi.nlm.nih.gov/40662109/

68.  U.S. study links ultra-processed foods to lower odds of fertility - News-Medical.Net, accessed on April 6, 2026, https://www.news-medical.net/news/20260322/US-study-links-ultra-processed-foods-to-lower-odds-of-fertility.aspx

69.  Association between ultra-processed foods and female infertility: a large cross-sectional study - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12220606/

70.  Do Popular Diets Impact Fertility? - MDPI, accessed on April 6, 2026, https://www.mdpi.com/2072-6643/16/11/1726

71.  Ultra-Processed Food Consumption Among College Students and Their Association With Body Composition, Bowel Movements and Menstrual Cycle - Journals, accessed on April 6, 2026, https://www.ssph-journal.org/journals/international-journal-of-public-health/articles/10.3389/ijph.2025.1607712/full

72.  Impact of psychological stress on ovarian function: Insights, mechanisms and intervention strategies (Review) - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11670866/

73.  Hypothalamic-Pituitary-Ovarian Axis, Ovarian Disorders, and Brain Aging - Oxford Academic, accessed on April 6, 2026, https://academic.oup.com/endo/article/166/10/bqaf137/8244475

74.  Chronic Stress and Ovulatory Dysfunction: Implications in Times of COVID-19 - Frontiers, accessed on April 6, 2026, https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2022.866104/full

75.  Lifestyle and fertility: the influence of stress and quality of life on female fertility - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6275085/

76.  Long-Term Effects of COVID-19 on Women's Reproductive Health and Its Association with Autoimmune Diseases, Including Multiple Sclerosis - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12072280/

77.  (PDF) Effect of Long-term COVID-19 on the Female Reproductive ..., accessed on April 6, 2026, https://www.researchgate.net/publication/389599402_Effect_of_Long-term_COVID-19_on_the_Female_Reproductive_System_A_Literature_Review

78.  Clinical Spectrum of Long COVID: Effects on Female Reproductive Health - PubMed, accessed on April 6, 2026, https://pubmed.ncbi.nlm.nih.gov/39066303/

79.  Unforeseen effects of COVID-19 on reproductive hormones and health of Indian women, accessed on April 6, 2026, https://www.ijrcog.org/index.php/ijrcog/article/view/13734

80.  Long term effects of COVID-19 infection on reproductive health of North Indian Women, accessed on April 6, 2026, https://healthcare-bulletin.co.uk/article/long-term-effects-of-covid-19-infection-on-reproductive-health-of-north-indian-women-4918/

81.  In-Vitro Fertilization Industry Report 2025-2033: Total Revenues to Exceed US$49 Billion by 2033 - Analysis of Regional Market Sizes and Shares of Major Players - ResearchAndMarkets.com - Business Wire, accessed on April 6, 2026, https://www.businesswire.com/news/home/20250408135187/en/In-Vitro-Fertilization-Industry-Report-2025-2033-Total-Revenues-to-Exceed-US%2449-Billion-by-2033---Analysis-of-Regional-Market-Sizes-and-Shares-of-Major-Players---ResearchAndMarkets.com

82.  What is the IVF Success Rate 2025? Key Factors Explained, accessed on April 6, 2026, https://risaaivf.com/what-is-the-ivf-success-rate-2025/

83.  IVF Success Rate In India For International Patients - Latest Data Year, accessed on April 6, 2026, https://worldfertilityservices.com/blog/ivf-success-rate-in-india-for-international-patients/

84.  ART Success Rate in India 2026 | Updated 2025 - We Care IVF Surrogacy, accessed on April 6, 2026, https://ivfsurrogacy.com/success-rates/

85.  ISAR GCPR - Indian Society For Assisted Reproduction, accessed on April 6, 2026, https://www.isarindia.net/pdf/ISAR-GCPR.pdf

86.  IVF Success Rate in India: Facts, Statistics & Real Outcomes - Fertycure, accessed on April 6, 2026, https://fertycure.com/ivf-success-rate-in-india-facts-statistics-real-outcomes/

87.  Assisted reproductive technology in India: A 3 year retrospective data analysis - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3963305/

88.  Artificial Intelligence-Empowered Embryo Selection for IVF Applications: A Methodological Review - MDPI, accessed on April 6, 2026, https://www.mdpi.com/2504-4990/7/2/56

89.  FERTILITY CARE IN LOW- AND MIDDLE- INCOME COUNTRIES: The future use of AI to improve accessibility of assisted reproductive technology in low - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12359024/

90.  How AI and Noninvasive Genetic Testing Are Improving IVF Success Rates | Jabalpur Fertility Centre, accessed on April 6, 2026, https://jabalpurivfcentre.com/blogs/how-ai-and-noninvasive-genetic-testing-are-improving-ivf-success-rates

91.  A review of artificial intelligence applications in in vitro fertilization - PMC - NIH, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11806189/

92.  Decoding the Epigenetics of Infertility: Mechanisms, Environmental Influences, and Therapeutic Strategies - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11417785/

93.  Latest Guidelines and gaps in the Laws & ART - Indian Fertility Society, accessed on April 6, 2026, https://indianfertilitysociety.org/wp-content/uploads/2025/07/IFSNewsletter-July-2025.pdf

94.  What to know about India's ART Regulation and Surrogacy Regulation Acts - Carrot Fertility, accessed on April 6, 2026, https://www.get-carrot.com/blog/what-to-know-about-indias-art-regulation-and-surrogacy-regulation-acts

95.  Legal subtleties of the Indian Assisted Reproductive Technology Act of 2021, accessed on April 6, 2026, https://nmji.in/legal-subtleties-of-the-indian-assisted-reproductive-technology-act-of-2021/

96.  The landscape of assisted reproductive technology access in India, accessed on April 6, 2026, https://raf.bioscientifica.com/downloadpdf/view/journals/raf/5/4/RAF-24-0079.pdf

97.  Assisted Reproductive Technology (Regulation) Act 2021: Critique and Contestations - PMC, accessed on April 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10994889/